High immunogenicity of red blood cell antigens restricted to the population of African descent in a cohort of sickle cell disease patients

Transfusion

Volumn 58, Issue 6, 2018, Pages 1527-1535

  Floch, Aline ^a,b,c,e   Gien, Dominique ^c,d   Tournamille, Christophe ^a,b,c   Chami, Btissam ^a   Habibi, Anoosha ^b,f   Galactéros, Frédéric ^b,f   Bierling, Philippe ^a,b,c,e,g   Djoudi, Rachid ^a   Pondarré, Corinne ^b,g   Peyrard, Thierry ^c,d   Pirenne, France ^a,b,c,e  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM U955   (France)

^c Laboratory of Excellence GR Ex   (France)

^d INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^e FACULTÉ DE MÉDECINE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIBODY; ERYTHROCYTE ANTIGEN; KEL6 ANTIBODY; KEL6 ANTIGEN; MNS6 ANTIBODY; MNS6 ANTIGEN; RH10 ANTIGEN; RH20 ANTIBODY; RH20 ANTIGEN; RH23 ANTIBODY; RH23 ANTIGEN; RH30 ANTIBODY; RH30 ANTIGEN; UNCLASSIFIED DRUG; ALLOANTIBODY; ALLOANTIGEN;

ADOLESCENT; ADULT; AFRICAN; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP FY SYSTEM; BLOOD GROUP JK SYSTEM; BLOOD GROUP MNSS SYSTEM; BLOOD GROUP SYSTEM; BLOOD SAMPLING; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; SEROPREVALENCE; SICKLE CELL ANEMIA; YOUNG ADULT; BLACK PERSON; BLOOD; BLOOD GROUP DUFFY SYSTEM; BLOOD GROUP KIDD SYSTEM; ERYTHROCYTE; IMMUNOLOGY;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANEMIA, SICKLE CELL; COHORT STUDIES; DUFFY BLOOD-GROUP SYSTEM; ERYTHROCYTES; HUMANS; ISOANTIBODIES; ISOANTIGENS; KIDD BLOOD-GROUP SYSTEM; MNSS BLOOD-GROUP SYSTEM;

EID: 85046021515     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14633     Document Type: Article

References (41)

1. Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years. Am J Hematol 2016; 1;91:5-14.
2. Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: prevention, diagnosis, treatment. Transfus Clin Biol 2017; 24:227-31.
3. Reid M, Lomas-Francis C, Olsson M. The blood group antigen factsbook. 3rd ed. San Diego: Academic Press; 2012. p. 758
4. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015;168:291-300.
5. Noizat-Pirenne F. Relevance of blood groups in transfusion of sickle cell disease patients. C R Biol 2013;336:152-8.
6. Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001;113:661-5.
7. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505-12.
8. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279-82.
9. Giblett ER. A critique of the theoretical hazard of inter vs. intra-racial transfusion. Transfusion 1961;1:233-8.
10. Winters JL, Pineda AA, Gorden LD, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 2001;41:1413-20.
11. Stack G, Tormey CA. Estimating the immunogenicity of blood group antigens: a modified calculation that corrects for transfusion exposures. Br J Haematol 2016;175:154-60.
12. French Health Ministry. Arrêté du 26 novembre 1999 relatif à la bonne exécution des analyses de biologie médicale modifié par l'Arrêté du 26 avril 2002. JORF 2002;104.
13. Omi T, Okuda H, Iwamoto S, et al. Detection of Rh23 in the partial D phenotype associated with the D(Va) category. Transfusion 2000;40:256-8.
14. Flegel WA, von Zabern I, Doescher A, et al. DCS-1, DCS-2, and DFV share amino acid substitutions at the extracellular RhD protein vestibule. Transfusion 2008;48:25-33.
15. Lopez GH, McGowan EC, McGrath KA, et al. A D+ blood donor with a novel RHD*D-CE(5-6)-D gene variant exhibits the low-frequency antigen RH23 (D(W)) characteristic of the partial DVa phenotype. Transfusion 2016;56:2322-30.
16. Chown B, Lewis M, Kaita HA. New Rh antigen and antibody. Transfusion 1962;2:150-4.
17. W (Wiel). Transfusion 1964;4:169-72.
18. Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion 2010;50:13-9.
19. Noizat-Pirenne F. Transfusion and sickle cell disease: axes of transfusion safety optimization. Transfus Clin Biol J Soc Francaise Transfus Sang 2014;21:77-84.
20. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990;76:1431-7.
21. Castro O, Sandler SG, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-90.
22. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol 2015;90:1135-41.
23. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122:1062-71.
24. Harm SK, Yazer MH, Monis GF, et al. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014;141:256-61.
25. Noizat-Pirenne F. Relevance of alloimmunization in haemolytic transfusion reaction in sickle cell disease. Transfus Clin Biol J Soc Francaise Transfus Sang 2012;19:132-8.
26. Larson PJ, Lukas MB, Friedman DF, et al. Delayed hemolytic transfusion reaction due to anti-Go(a), an antibody against the low-prevalence Gonzales antigen. Am J Hematol 1996;53:248-50.
27. Anderson RR, Sosler SD, Kovach J, et al. Delayed hemolytic transfusion reaction due to anti-Js(a) in an alloimmunized patient with a sickle cell syndrome. Am J Clin Pathol 1997;108:658-61.
28. Taddie SJ, Barrasso C, Ness PM. A delayed transfusion reaction caused by anti-K6. Transfusion 1982;22:68-9.
29. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
30. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion 2016;56:107-14.
31. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007;92:e132-5.
32. Noizat-Pirenne F, Habibi A, Mekontso-Dessap A, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang 2015;108:262-7.
33. Donovan LM, Tripp KL, Zuckerman JE, et al. Hemolytic disease of the newborn due to anti-Js a. Transfusion 1973;13:153.
34. Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2012;52:381-8.
35. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011;51:1732-9.
36. Natukunda B, Schonewille H, Ndugwa C, et al. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion 2010;50:20-5.
37. Klapper E, Zhang Y, Figueroa P, et al. Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 2010;50:536-46.
38. Karafin MS, Field JJ, Gottschall JL, et al. Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease. Transfusion 2015;55:1399-406.
39. Kacker S, Ness PM, Savage WJ, et al. Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. Transfusion 2014;54:2034-44.
40. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 2014;99:e115-7.
41. Yee ME, Josephson CD, Winkler AM, et al. Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia. Transfusion 2017;57:2738-46.